Toll-like Receptor (TLR) Agonist

TLR7 agonist 16 (compound 16d) is a highly potent TLR7 agonist with an EC₅₀ of 18 nM. TLR7 agonist 16 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.

GAP214 is a monosaccharide lipid A analogue and TLR4/MD-2 complex modulator.GAP214 binds to the TLR4/MD-2 complex via hydrophobic interactions, salt bridges, and hydrogen bonds, induces dimerization of the complex to initiate intracellular signaling cascades.GAP214 functions as an immunostimulant and vaccine adjuvant, enhances antigen-specific IgG antibody production in a mouse model.

m-AM-BBIQ (compound 10) is a dual TLR7 and TLR8 agonist, with EC₅₀ values of 0.12 μM and 1.7 μM for hTLR7 and hTLR8, respectively.

Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM.

Cobitolimod sodium scrambled negative control is the sequence scrambled negative control of Cobitolimod sodium.

AYK004-C1 is a TLR agonist. AYK004-C1 can be used to prepare immune adjuvants.

SMU-L11-R is a selective TLR7 agonist with an EC₅₀ of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8⁺T cells. SMU-L11-R shows potential in colorectal cancer studies.

TLR7 agonist 8 is a TLR7 agonist with an EC₅₀ of 0.12 nM for TLR7 and an EC₅₀ of 0.76 nM for IL-6 induction. TLR7 agonist 8 can be used for research on diseases such as fibrosis, inflammatory diseases, cancer, or pathogen infections.

TLR7 agonist 15 (compound 16b) is a highly potent TLR7 agonist with an EC₅₀ of 18 nM. TLR7 agonist 15 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.

TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.

Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway.

Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

TLR7 agonist 18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 7.8 μM. TLR7 agonist 18 is not cytotoxic to hTLR7 cotransfected HEK293 cell lines and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. TLR7 agonist 18 can be used in vaccine, asthma, allergy and anti-cancer research.

CpG-ODN c41 sodium, an oligonucleotide, is an antagonist of TLR9.

TLR7 agonist 33 (Compound 141) is a potent TLR7 activator with an EC₅₀ of 1 nM. TLR7 agonist 33 can be used for cancer research.

AYK005 is a TLR7/8 immunologic adjuvant.

TLR7 agonist 26 (Compound 4) is a potent Toll-like receptor 7 (TLR7) agonist, with an EC₅₀ of 225.5 nM. TLR7 agonist 26 shows immunopotentiating effects.

AZ12441970 is a potent and selectiveToll-like receptor 7 (TLR7) agonist, exhibiting pEC₅₀s of 6.8 and 6.6 for human and rat TLR7. AZ12441970 shows efficacy in a mouse allergic airway model with minimal induction of systemic IFN-α. AZ12441970 can be used for allergic airway disease research.

TLR7 agonist 14 (compound 17b) is a highly potent TLR7 agonist with an EC₅₀ of 18 nM. TLR7 agonist 14 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.

Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.